{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T01:40:44Z","timestamp":1760492444529,"version":"build-2065373602"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14911-5","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:40:59Z","timestamp":1760449259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Telpegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in patients with high- or medium-risk non-myeloid malignancies: a multicenter, retrospective study"],"prefix":"10.1186","volume":"25","author":[{"given":"Yanbing","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongming","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"3","key":"14911_CR1","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2354.2008.00959.x","volume":"18","author":"D Almenar","year":"2009","unstructured":"Almenar D, Mayans J, Juan O, Bueno JM, Lopez JI, Frau A, et al. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain\u2013results of the LEARN Study. Eur J Cancer Care. 2009;18(3):280\u20136. https:\/\/doi.org\/10.1111\/j.1365-2354.2008.00959.x.","journal-title":"Eur J Cancer Care."},{"key":"14911_CR2","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.ctrv.2022.102427","volume":"109","author":"DW Blayney","year":"2022","unstructured":"Blayney DW, Schwartzberg L. Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review. Cancer Treat Rev. 2022;109:102427. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102427.","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"14911_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228\u201337. https:\/\/doi.org\/10.1002\/cncr.11882.","journal-title":"Cancer."},{"issue":"suppl 5","key":"14911_CR4","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdw325.","journal-title":"Ann Oncol."},{"key":"14911_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2017.11.005","volume":"120","author":"Y Lalami","year":"2017","unstructured":"Lalami Y, Klastersky J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol. 2017;120:163\u201379. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.11.005.","journal-title":"Crit Rev Oncol Hematol."},{"issue":"9","key":"14911_CR6","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s00520-017-3692-x","volume":"25","author":"AA Kawatkar","year":"2017","unstructured":"Kawatkar AA, Farias AJ, Chao C, Chen W, Barron R, Vogl FD, et al. Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population. Support Care Cancer. 2017;25(9):2787\u201395. https:\/\/doi.org\/10.1007\/s00520-017-3692-x.","journal-title":"Support Care Cancer."},{"issue":"Supplement 1","key":"14911_CR7","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1182\/blood-2022-165527","volume":"140","author":"SS Makhani","year":"2022","unstructured":"Makhani SS, Abro C, Ketineni S, Zhu X, Prakash V, Agarwal I, et al. Inpatient Burden and Clinical Outcomes of Febrile Neutropenia in Cancer Patients: A National Inpatient Sample Database Analysis. Blood. 2022;140(Supplement 1):5154\u20135. https:\/\/doi.org\/10.1182\/blood-2022-165527.","journal-title":"Blood."},{"issue":"8","key":"14911_CR8","doi-asserted-by":"publisher","first-page":"e1348","DOI":"10.1002\/iid3.1348","volume":"12","author":"C Mao","year":"2024","unstructured":"Mao C, He Y, Xu N, Yan H, Zhang N, Cheng G, et al. A multicenter, prospective, non-interventional real-world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer. Immun Inflamm Dis. 2024;12(8):e1348. https:\/\/doi.org\/10.1002\/iid3.1348.","journal-title":"Immun Inflamm Dis."},{"key":"14911_CR9","doi-asserted-by":"publisher","first-page":"S1098","DOI":"10.1016\/j.annonc.2023.09.871","volume":"34","author":"Y Zhang","year":"2023","unstructured":"Zhang Y. 2089P Multi-cycle prophylaxis of long-acting granulocyte colony-stimulating factor in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy: A retrospective real-world study in China. Ann Oncol. 2023;34:S1098. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.871.","journal-title":"Ann Oncol."},{"issue":"1","key":"14911_CR10","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1186\/s12885-023-11198-2","volume":"23","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Zhang J, Zhong J, Liao H, Zhang J, Liu Y, et al. Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients. BMC Cancer. 2023;23(1):702. https:\/\/doi.org\/10.1186\/s12885-023-11198-2.","journal-title":"BMC Cancer."},{"issue":"6","key":"14911_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3816\/cbc.2003.n.003","volume":"3","author":"E Kubista","year":"2003","unstructured":"Kubista E, Glaspy J, Holmes FA, Green MD, Hackett J, Neumann T. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer. 2003;3(6):391\u20138. https:\/\/doi.org\/10.3816\/cbc.2003.n.003.","journal-title":"Clin Breast Cancer."},{"key":"14911_CR12","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1182\/blood-2019-128438","volume":"134","author":"C Zhen","year":"2019","unstructured":"Zhen C, Ding M, Lu K, Ge X, Chen N, Fang X, et al. A Randomized Controlled Clinical Study of Peg-Rhg-CSF for Preventing Chemotherapy-Induced Neutropenia in Patients with B-Cell Non-Hodgkin Lymphoma. Blood. 2019;134:5323. https:\/\/doi.org\/10.1182\/blood-2019-128438.","journal-title":"Blood."},{"key":"14911_CR13","doi-asserted-by":"publisher","first-page":"S1635","DOI":"10.1016\/j.annonc.2023.10.527","volume":"34","author":"Y Shi","year":"2023","unstructured":"Shi Y, Zhang Q, Wang X, Pei Z, Wang J, Yi T, et al. 441P The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study. Ann Oncol. 2023;34:S1635. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.527.","journal-title":"Ann Oncol."},{"issue":"12","key":"14911_CR14","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.procbio.2007.09.005","volume":"42","author":"X-Q Li","year":"2007","unstructured":"Li X-Q, Lei J-D, Su Z-G, Ma G-H. Comparison of bioactivities of monopegylated rhG-CSF with branched and linear mPEG. Process Biochem. 2007;42(12):1625\u201331. https:\/\/doi.org\/10.1016\/j.procbio.2007.09.005.","journal-title":"Process Biochem."},{"issue":"7","key":"14911_CR15","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1021\/bc300066a","volume":"23","author":"Y Vugmeyster","year":"2012","unstructured":"Vugmeyster Y, Entrican CA, Joyce AP, Lawrence-Henderson RF, Leary BA, Mahoney CS, et al. Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethylene glycol). Bioconjug Chem. 2012;23(7):1452\u201362. https:\/\/doi.org\/10.1021\/bc300066a.","journal-title":"Bioconjug Chem."},{"issue":"20","key":"14911_CR16","doi-asserted-by":"publisher","first-page":"e33638","DOI":"10.1097\/md.0000000000033638","volume":"102","author":"K Park","year":"2023","unstructured":"Park K, Jeon YK, Kim JH, Choi Y, Kim JJ, Oh SB, et al. Comparison of prophylactic effects for chemotherapy induced neutropenia between same-day versus next-day administration of pegteograstim (Neurapeg\u00ae) in patients treated with chemotherapy regimen composed of day 1 intensive myleosuppressive agent: A randomized phase III clinical trial. Medicine. 2023;102(20):e33638. https:\/\/doi.org\/10.1097\/md.0000000000033638.","journal-title":"Medicine."},{"key":"14911_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e12516","author":"L Zhang","year":"2022","unstructured":"Zhang L, Li Y, Fan Z, Wang M, Hui T, Zhang Y, et al. A randomized trial of pegylated recombinant human granulocyte-colony stimulating factor to prevent febrile neutropenia in breast cancer after chemotherapy. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e12516.","journal-title":"J Clin Oncol."},{"issue":"Supplement 1","key":"14911_CR18","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1182\/blood-2024-206847","volume":"144","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Zou S, Lin J, Wang J, Wang C, Chen G, et al. Efficacy and Safety of Telpegfilgrastim in the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Lymphoma: A Retrospective Study. Blood. 2024;144(Supplement 1):6523. https:\/\/doi.org\/10.1182\/blood-2024-206847.","journal-title":"Blood."},{"issue":"5","key":"14911_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10147-024-02499-y","volume":"29","author":"Y Ozaki","year":"2024","unstructured":"Ozaki Y, Yokoe T, Yoshinami T, Nozawa K, Nishio H, Tsuchihashi K, et al. Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022. Int J Clin Oncol. 2024;29(5):551\u20138. https:\/\/doi.org\/10.1007\/s10147-024-02499-y.","journal-title":"Int J Clin Oncol."},{"key":"14911_CR20","unstructured":"Griffiths EA, Roy V, Asif S, Bachiashvili K, Baird J, Bakhshi S, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Hematopoietic Growth Factors, Version 1.2025. 2024."},{"issue":"1","key":"14911_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/pro6.1107","volume":"5","author":"J Wang","year":"2021","unstructured":"Wang J, Li B. Chinese Association for Therapeutic Radiation Oncologists CSfRO, Chinese association of radiation therapy. Chinese expert consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy\u00a0(2020 edition). Precis Rad Oncol. 2021;5(1):4\u201311. https:\/\/doi.org\/10.1002\/pro6.1107.","journal-title":"Precis Rad Oncol."},{"key":"14911_CR22","doi-asserted-by":"publisher","unstructured":"China Anti-Cancer Association Tumor Clinical Chemotherapy Professional Committee; China Anti-Cancer Association Tumor Support Therapy Professional Committee. [Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2023 edition)]. Zhonghua Zhong Liu Za Zhi. 2023;45(7):575\u221283. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20230224-00076","DOI":"10.3760\/cma.j.cn112152-20230224-00076"},{"key":"14911_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e24119","author":"L Xing","year":"2024","unstructured":"Xing L, Zhao L, Li D, Yang Z, Chen Y, Ye H, et al. Efficacy and safety of mecapegfilgrastim in preventing neutropenia during concurrent chemoradiotherapy. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e24119.","journal-title":"J Clin Oncol"},{"issue":"2","key":"14911_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3816\/CCC.2010.n.013","volume":"9","author":"JR Hecht","year":"2010","unstructured":"Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, et al. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer. 2010;9(2):95\u2013101. https:\/\/doi.org\/10.3816\/CCC.2010.n.013.","journal-title":"Clin Colorectal Cancer."},{"issue":"26","key":"14911_CR25","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.2217\/fon-2021-0532","volume":"17","author":"A McBride","year":"2021","unstructured":"McBride A, Alrawashdh N, Bartels T, Moore L, Persky D, Abraham I. Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy. Fut Oncol. 2021;17(26):3485\u201397.","journal-title":"Fut Oncol."},{"key":"14911_CR26","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404. https:\/\/doi.org\/10.1186\/1471-2407-11-404.","journal-title":"BMC Cancer."},{"issue":"1","key":"14911_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood.v80.1.3.3","volume":"80","author":"MA Moore","year":"1992","unstructured":"Moore MA. Does stem cell exhaustion result from combining hematopoietic growth factors with chemotherapy? If so, how do we prevent it? Blood. 1992;80(1):3\u20137. https:\/\/doi.org\/10.1182\/blood.v80.1.3.3.","journal-title":"Blood."},{"issue":"2","key":"14911_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-2257.1993.tb00130.x","volume":"15","author":"MG Macey","year":"1993","unstructured":"Macey MG, Sangster J, Kelsey SM, Newland AC. Pilot study: effects of G-CSF on neutrophil ex-vivo function post bone marrow transplantation. Clin Lab Haematol. 1993;15(2):79\u201385. https:\/\/doi.org\/10.1111\/j.1365-2257.1993.tb00130.x.","journal-title":"Clin Lab Haematol."},{"issue":"10","key":"14911_CR29","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1111\/bcp.16151","volume":"90","author":"S Yang","year":"2024","unstructured":"Yang S, Chen SS, Zhang CG, Zhou YL, Xiu M, Zhang P. Low-dose pegylated recombinant human granulocyte-colony stimulating factor as hematopoietic support for adjuvant chemotherapy in Chinese patients with breast cancer: An open-label, randomized, non-inferiority trial. Br J Clin Pharmacol. 2024;90(10):2621\u20139. https:\/\/doi.org\/10.1111\/bcp.16151.","journal-title":"Br J Clin Pharmacol."},{"issue":"9","key":"14911_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.21037\/atm.2019.04.10","volume":"7","author":"T Wang","year":"2019","unstructured":"Wang T, Wu B, Hu X, Liu J, Zhang T, Li F, et al. A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients. Ann Transl Med. 2019;7(9):196. https:\/\/doi.org\/10.21037\/atm.2019.04.10.","journal-title":"Ann Transl Med."},{"key":"14911_CR31","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3332\/ecancer.2021.1188","volume":"15","author":"O Salako","year":"2021","unstructured":"Salako O, Okunade KS, Adeniji AA, Fagbenro GT, Afolaranmi OJ. Chemotherapy induced neutropenia and febrile neutropenia among breast cancer patients in a tertiary hospital in Nigeria. Ecancermedicalscience. 2021;15:1188. https:\/\/doi.org\/10.3332\/ecancer.2021.1188.","journal-title":"Ecancermedicalscience."},{"issue":"12","key":"14911_CR32","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00520-023-08071-0","volume":"31","author":"B Leon Rapoport","year":"2023","unstructured":"Leon Rapoport B, Garcia-Morillo M, Font C, Samoon Z, Jabbar AA, Kourie HR, et al. A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative. Support Care Cancer. 2023;31(12):628. https:\/\/doi.org\/10.1007\/s00520-023-08071-0.","journal-title":"Support Care Cancer."},{"issue":"5 Suppl 4","key":"14911_CR33","first-page":"11","volume":"20","author":"H Ozer","year":"2006","unstructured":"Ozer H. The timing of chemotherapy-induced neutropenia and its clinical and economic impact. Oncology (Williston Park). 2006;20(5 Suppl 4):11\u20135.","journal-title":"Oncology (Williston Park)."},{"key":"14911_CR34","doi-asserted-by":"publisher","first-page":"1405210","DOI":"10.3389\/fimmu.2024.1405210","volume":"15","author":"K Faltusov\u00e1","year":"2024","unstructured":"Faltusov\u00e1 K, B\u00e1je\u010dn\u00fd M, Heizer T, P\u00e1ral P, Chen CL, Szikszai K, et al. Second bone marrow transplantation into regenerating hematopoiesis enhances reconstitution of immune system. Front Immunol. 2024;15:1405210. https:\/\/doi.org\/10.3389\/fimmu.2024.1405210.","journal-title":"Front Immunol."},{"issue":"15_suppl","key":"14911_CR35","doi-asserted-by":"publisher","first-page":"e19051","DOI":"10.1200\/JCO.2019.37.15_suppl.e19051","volume":"37","author":"J Zhu","year":"2019","unstructured":"Zhu J, Li H, Fan Z, Gao Y, Tu M, Shao B, et al. Efficacy and safety of PEG-rhG-CSF in primary and secondary prevention of chemotherapy-induced neutropenia. J Clin Oncol. 2019;37(15_suppl):e19051. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.e19051.","journal-title":"J Clin Oncol."},{"issue":"16","key":"14911_CR36","doi-asserted-by":"publisher","first-page":"e24107","DOI":"10.1200\/JCO.2024.42.16_suppl.e24107","volume":"42","author":"J Zhao","year":"2024","unstructured":"Zhao J, Wang H, Zhang G, Zhang X, Du Y, Ma N, et al. Safety and efficacy of PEG-rhG-CSF as primary prophylaxis against neutropenia induced by combination chemotherapy regimens involving oral chemotherapy agents in gastrointestinal cancer patients: A prospective, exploratory, non-randomized controlled study. J Clin Oncol. 2024;42(16):e24107. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e24107.","journal-title":"J Clin Oncol."},{"key":"14911_CR37","doi-asserted-by":"publisher","first-page":"690874","DOI":"10.3389\/fphar.2021.690874","volume":"12","author":"Q Wu","year":"2021","unstructured":"Wu Q, Li Q, Zhang J, Luo Z, Zhou J, Chen J, et al. Comparison of Primary and Secondary Prophylaxis Using PEGylated Recombinant Human Granulocyte-Stimulating Factor as a Cost-Effective Measure in Malignant Neoplasms: A Multicenter Retrospective Study. Front Pharmacol. 2021;12:690874. https:\/\/doi.org\/10.3389\/fphar.2021.690874.","journal-title":"Front Pharmacol."},{"issue":"1","key":"14911_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","volume":"89","author":"M Lambertini","year":"2014","unstructured":"Lambertini M, Del Mastro L, Bellodi A, Pronzato P. The five \u201cWs\u201d for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol. 2014;89(1):112\u201328. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.08.006.","journal-title":"Crit Rev Oncol Hematol."},{"issue":"2","key":"14911_CR39","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/j.pmn.2023.12.004","volume":"25","author":"J Mazzola","year":"2024","unstructured":"Mazzola J, Hennon P, Peine K, Siedlecki SL. Effect of Loratadine for Pegfilgrastim-Induced Bone Pain. Pain Manag Nurs. 2024;25(2):e132\u20137. https:\/\/doi.org\/10.1016\/j.pmn.2023.12.004.","journal-title":"Pain Manag Nurs."},{"key":"14911_CR40","doi-asserted-by":"publisher","unstructured":"Zhang X, Wang Y, Liu F, Chen L, Peng L, Qiu X, et al. Comparing the efficacy and safety of long and short acting drugs targeting Granulocyte Colony-stimulating Factor in cancer patients after chemotherapy: A systematic review and meta-analysis of randomized controlled trials. 2020. https:\/\/doi.org\/10.21203\/rs.2.24307\/v1","DOI":"10.21203\/rs.2.24307\/v1"},{"issue":"2","key":"14911_CR41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1188\/20.Cjon.165-169","volume":"24","author":"E McLean","year":"2020","unstructured":"McLean E. Acute Bone Pain: An analysis of symptom management interventions after administration of granulocyte-colony-stimulating factors for myelosuppression. Clin J Oncol Nurs. 2020;24(2):165\u20139. https:\/\/doi.org\/10.1188\/20.Cjon.165-169.","journal-title":"Clin J Oncol Nurs."},{"issue":"15_suppl","key":"14911_CR42","doi-asserted-by":"publisher","first-page":"20636","DOI":"10.1200\/jco.2008.26.15_suppl.20636","volume":"26","author":"C Paba","year":"2008","unstructured":"Paba C, Sachdev J, Kronish L, Jahanzeb M, Waheed S. Empiric dose reduction of pegfilgrastim in breast cancer patients receiving cytotoxic chemotherapy. J Clin Oncol. 2008;26(15_suppl):20636. https:\/\/doi.org\/10.1200\/jco.2008.26.15_suppl.20636.","journal-title":"J Clin Oncol."},{"issue":"12","key":"14911_CR43","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1080\/03007995.2017.1386638","volume":"33","author":"D Weycker","year":"2017","unstructured":"Weycker D, Bensink M, Wu H, Doroff R, Chandler D. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010 to 2015. Curr Med Res Opin. 2017;33(12):2115\u201320. https:\/\/doi.org\/10.1080\/03007995.2017.1386638.","journal-title":"Curr Med Res Opin."},{"key":"14911_CR44","doi-asserted-by":"publisher","first-page":"795650","DOI":"10.3389\/fonc.2021.795650","volume":"11","author":"Q Ji","year":"2021","unstructured":"Ji Q, Ding J, Hao M, Luo N, Huang J, Zhang W. Immune checkpoint inhibitors combined with chemotherapy compared with chemotherapy alone for triple-negative breast cancer: a systematic review and meta-analysis. Front Oncol. 2021;11:795650. https:\/\/doi.org\/10.3389\/fonc.2021.795650.","journal-title":"Front Oncol."},{"issue":"2","key":"14911_CR45","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/cm9.0000000000003298","volume":"138","author":"W Fu","year":"2025","unstructured":"Fu W, Jiang Y, Ye W, Zhong R, Xiong S, Li J, et al. Incidence of hematological toxicity with use of immunotherapy and chemotherapy in advanced non-small cell lung cancer. Chin Med J. 2025;138(2):249\u201351. https:\/\/doi.org\/10.1097\/cm9.0000000000003298.","journal-title":"Chin Med J."},{"key":"14911_CR46","doi-asserted-by":"publisher","unstructured":"McBride A, Alrawashdh N, Bartels T, Moore L, Persky D, Abraham I. Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy. Future Oncol. 2021;17(26):3485\u201397. https:\/\/doi.org\/10.2217\/fon-2021-0532.","DOI":"10.2217\/fon-2021-0532"},{"key":"14911_CR47","doi-asserted-by":"publisher","unstructured":"Kitchen K, Mosier MC. Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy. Future Oncol. 2022;18(23):2551\u201360. https:\/\/doi.org\/10.2217\/fon-2022-0365.","DOI":"10.2217\/fon-2022-0365"},{"key":"14911_CR48","doi-asserted-by":"publisher","unstructured":"Zullo AR, Lou U, Cabral SE, Huynh J, Berard-Collins CM. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia. J Oncol Pharm Pract. 2019;25(6):1357\u201365. https:\/\/doi.org\/10.1177\/1078155218792698.","DOI":"10.1177\/1078155218792698"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14911-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14911-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14911-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T01:05:16Z","timestamp":1760490316000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14911-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14911"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14911-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Independent Ethics Committee of the main center, the Clinical Oncology School of Fujian Medical University and Fujian Cancer Hospital per the Declaration of Helsinki, with the ethics approval number (No.K2024-414-01). The principal investigators from the other participating centers submitted ethical applications at the three institutions of the Research Ethics Committee of Shulan (Hangzhou) Hospital, the Ethics Committee of Jiangsu Cancer Hospital, and the First Ethics Committee of Henan Cancer Hospital\u2019s Medical Ethics Committee, and all were approved. The ethics approval numbers are as follows: KY2024079 for Shulan (Hangzhou) Hospital, 2025-398-001 for Henan Cancer Hospital, and KY-2025-118 for Jiangsu Cancer Hospital. As this study is retrospective, informed consent is waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1571"}}